dentifier: anf-body-

31, inlineTextStyles: [{range:{lengt
im}, {range™:{Llength:226, start:0},t
body, role:body, text:In 2000, the
that it had evidence the company was imp
cancers as well as to promote a feeling

patients.,type™: text }, {identifier:
32,inlineTextStyles: [{range: {lengt
im}, {range:{Llength:175, start:0},t

h:226,start:0},textStyle: anf-ts-
extStyle™: anf-ts-1}],layout™:default-
agency issued a formal warning letter, saying
roperly marketing Thalomid for a variety of
of a€egeneral well-beinga€ in cancer
_anf-body-
h:175,start:0},textStyle: anf-ts-
extStyle™: anf-ts-1}],layout:default-

body, role: body, text: a€ePerhaps more than for any other available drug, the need

to provide and distribute thalidomide re
the agency wrote in the

letter., type: text }, {additions:[{
16284/000100515001000229/0001005150-01-
000229.txt, range: {length:20,start
33,inlineTextStyles: [{range:{lengt
i},{range™:{Llength:517,start:0},t
body, role: body, text:Over the nex

sponsibly is essential to the public health, a4€
URL: https://www.sec.gov/Archives/edgar/data/8
7286}, type™:link}],identifier: anf-body-

h:517,start:0},textStyle: anf-ts-
extsStyle™: anf-ts-1}],layout™:default-

t few years, however, Mr. Hugin and other top

xecutives repeatedly referred to Thalomid 4€ and later Revlimid 4€ as the key to

Celgenead€™s financial future, even thoug
the drugs to treat certain cancers until
that 92 percent of Thalomidad€™s prescrip
at an investor conference in 2004, Mr. H
is the financial engine that drives us.4
34, inlineTextStyles: [{range:{lengt
1},{range™:{Llength:171,start:0},t
body, role: body, text:Celgene has

saying it settled the lawsuit in 2017 to
of protracted litigation.ad€, type: tex
35, “anlineTextstyles: [{range:{lengt
1},{range:{length:186, start:0},t

h it would not get formal approval to market
2005 and 2006. In 2001, the company reported
tions were being written to treat cancer, and
ugin said, a€eThalomid is important, because it

€, type™:text}, {identifier: anf-body-
h:171,start:0},textStyle: anf-ts-
extsStyle™: anf-ts-1}],layout™:default-

denied that it engaged in illegal marketing,
avoid the uncertainty, distraction and expense

t}, {identifier: anf-body-
h:186,start:0},textStyle: anf-ts-
extStyle™: anf-ts-1}],layout:default-

body, role:body, text: The incredib
promising treatments for multiple myelom
patients a year, was a windfall for
Celgene., type: text}, {additions: [{
s/revlimid-long-

form.pdi, range: {length:17,start:2
36, inlineTextStyles: [{range:{lengt
1},{range:{Llength:218, start:0},t
body, role: body, text:Introduced t
Revlimid, a closely related derivative o
2017, Celegene had raised the price of a
$16,000.,type™:text}, {identifier™:

le demand for Thalomid, and later Revlimid, as
a, a disease that affects more than 30,000

URL: https://media.celgene.com/content/upload

00}, type™:link}],identifier: anf-body-
h:218,start:0},textStyle: anf-ts-
extsStyle™: anf-ts-1}],layout™:default-

o the market in 2006, a monthda€™s supply of

f thalidomide, initially cost about $6,000. By
montha€™s supply to more than

anf-heading4-

3, Layout: heading4, role: heading4, text:A brutal battle to fend off generic

drug makers, type: text}, {identifier
37, inlineTextStyles: [{range: {lengt
im}, {range™:{Length:328,start:0},t
body, role:body, text:The company

: anf-body-
h:328,start:0},textStyle: anf-ts-
extstyle™: anf-ts-1}],layout™:default-

was able to aggressively raise prices in part

as a result of its legal monopoly. Under
can exclusively market a drug for up to

with any patents, the market opens to ge
precipitously., type: text}, {identift
38, inlineTextStyles: [{range:{lengt
im}, {range™:{Llength:113, start:0},t
body, role:body, text:To protect t
mounted an aggressive campaign to extend
monopoly., type: text}, {identifier™:
39,inlineTextstyles: [{range:{leng
1},{range: {length:269, start:0},
body, role: body, text: 4€eTheyae™ve
drug and to build as many walls around i
president for federal government affairs
the generic drug industryde™s lobbying g
40, inlineTextStyles: [{range:{lengt
i},{range™:{length:145, start:0},t

federal regulations, a pharmaceutical company
seven years. Once that period expires, along
neric competition and prices typically fall

ier:_ anf-body-
h:113,start:0},textStyle: anf-ts-
extsStyle™: anf-ts-1}],layout™:default-

he profits from Revlimid and Thalomid, Celgene
its

_anf-body-
h:269,start:0},textStyle: anf-ts-
extsStyle™: anf-ts-1}],layout:default-

gone to pretty great lengths to protect that

t as they can,a4€ said Michael Brzica, the vice
at the Association for Accessible Medicines,
roup., type: text}, {identifier: anf-body-
h:145,start:0},textStyle: anf-ts-
extsStyle™: anf-ts-1}],layout™:default-

body, role: body, text:Celgene has been repeatedly accused of restricting access

to samples of its drugs, which generic c

ompanies need to test their competing

HOUSE_OVERSIGHT_028419
